227 related articles for article (PubMed ID: 24741631)
1. Ursodeoxycholic acid influences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis.
Milkiewicz M; Kopycińska J; Kempińska-Podhorodecka A; Haas T; Bogdanos DP; Elias E; Milkiewicz P
J Immunol Res; 2014; 2014():921285. PubMed ID: 24741631
[TBL] [Abstract][Full Text] [Related]
2. Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis.
Kopycinska J; Kempińska-Podhorodecka A; Haas T; Elias E; DePinho RA; Paik J; Milkiewicz P; Milkiewicz M
Liver Int; 2013 Feb; 33(2):231-8. PubMed ID: 23295054
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
4. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
[TBL] [Abstract][Full Text] [Related]
5. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
[TBL] [Abstract][Full Text] [Related]
6. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis.
Neuman M; Angulo P; Malkiewicz I; Jorgensen R; Shear N; Dickson ER; Haber J; Katz G; Lindor K
J Gastroenterol Hepatol; 2002 Feb; 17(2):196-202. PubMed ID: 11966951
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
9. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
10. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway.
Kempinska-Podhorodecka A; Milkiewicz M; Wasik U; Ligocka J; Zawadzki M; Krawczyk M; Milkiewicz P
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146070
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis.
Sakisaka S; Koga H; Sasatomi K; Ohishi M; Kawaguchi T; Harada M; Taniguchi E; Uchimura Y; Ueno T; Sata M; Tanikawa K
Liver; 2000 Feb; 20(1):78-87. PubMed ID: 10726964
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.
Shimoyama S; Kawata K; Ohta K; Chida T; Suzuki T; Tsuneyama K; Shimoda S; Kurono N; Leung PSC; Gershwin ME; Suda T; Kobayashi Y
Eur J Immunol; 2021 Jun; 51(6):1519-1530. PubMed ID: 33710617
[TBL] [Abstract][Full Text] [Related]
14. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
[TBL] [Abstract][Full Text] [Related]
16. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
Zein CO; Lindor KD
Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to Toll-like receptor ligands in primary biliary cirrhosis.
Qin B; Wei T; Wang L; Ma N; Tang Q; Liang Y; Yang Z; Zhou L; Zhong R
J Gastroenterol Hepatol; 2016 Jun; 31(6):1177-83. PubMed ID: 26644386
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
